Close Menu

GenomeWeb

Using genome sequence data for more than 2,500 tumors, researchers saw signs that some passenger mutations may act together to influence tumor features and growth.

CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

The single-cell analysis and spatial genomics company reported $75.3 million in Q4 revenues. Full year revenues grew 68 percent to $245.9 million.

Although polygenic risk scores for coronary artery disease can slightly improve standard risk assessment tools, the predicted clinical impact remains small.

At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.

The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.

Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.

In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.

Dec
06
Sponsored by
MNG Laboratories

Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers. 

Oct
25
Sponsored by
MNG Laboratories

Join us for a webinar presented by our Chief Medical Officer, Dr. Peter L. Nagy, to discuss the benefits of performing and analyzing genome and RNA sequencing together. The increased number of single nucleotide and copy number variants associated with genome sequencing are best interpreted with the help of joint parental testing and the assessment of the functional significance of intronic and regulatory changes with a functional test like the transcriptome.